Etanercept biosimilar approval reignites ‘a-flagging’ concerns


The recent TGA approval of the etanercept biosimilar Brenzys™ has reignited concerns around the pharmacist substitution of originator biologics for biosimilars. Marketed by MSD in Australia Brenzys™ is the first biosimilar of Pfizer’s originator drug Enbrel™ and follows hot on the heels of the infliximab biosimilar Inflectra™ which received  a PBS listing in December last ...


Already a member? Login to keep reading


OR
© 2017 the limbic